These observations confirm that inhibiting the non-canonical NF-κB signaling pathway sensitizes resistant CLL cells to venetoclax by inhibiting the expression of Bcl-XL. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.